Ask AI

Oncology Pharmacy Think Tank: Patient-Centered Management of CDK4/6 Inhibitor Therapy for HR+/HER2- Breast Cancer

Optimize care for your patients with HR-positive/HER2-negative breast cancer by enhancing your understanding of CDK4/6 inhibitors and their associated toxicities through certified interactive case challenges, a certified podcast, and downloadable slides.

Share

Program Content

Activities

CDK46 Inhibitors for Breast Cancer
Oncology Pharmacy Think Tank: Patient-Centered Management of CDK4/6 Inhibitor Therapy for HR+/HER2- Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 10, 2026

Activities

CDK46i Adherence mBC
Improving Adherence to Oral CDK4/6 Inhibitors in HR+/HER2- mBC
Case Challenge
Congratulations: You achieved a completion on 04/09/2022

Released: December 31, 2025

Expires: June 30, 2026

Adjuvant CDK4/6i in HR Pos EBC
Adjuvant CDK4/6 Inhibitors in High-Risk HR+/HER2− EBC: Managing AEs and Administration Considerations to Optimize Adherence
Case Challenge
Congratulations: You achieved a completion on 04/09/2022

Released: January 29, 2026

Expires: July 28, 2026

Provided by

ProCE Banner

Provided by ProCE, LLC in collaboration with Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by educational grants from Lilly.

Lilly

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner